Literature DB >> 454671

Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol.

K V Savoca, A Abuchowski, T van Es, F F Davis, N C Palczuk.   

Abstract

Methoxypolyethylene glycol of 5000 daltons (PEG) was attached covalently to bovine liver arginase using 2,4,6-trichloro-s-triazine as the coupling agent. The conjugate (PEG-arginase), with PEG attached to 53% of the amino groups, retained 65% of its original enzymatic activity. Mice were injected intravenously with arginase or PEG-arginase for periods of one to three months. The blood-circulating life of PEG-arginase was greatly extended over that of arginase. The half-life of injected arginase at day 30 was less than 1 h, whereas that of the PEG-enzyme was 12 h. Antisera from mice injected with native arginase reacted against arginase but not against PEG-arginase when tested by immunodiffusion. Antisera from animals injected with PEG-arginase reacted neither with native arginase nor PEG-arginase. The data indicate that arginase modified by PEG has been rendered both non-immunogenic and non-antigenic when tested in mice. The injection of PEG-arginase into mice did not induce tolerance toward the native enzyme. Injected PEG-arginase, in the presence of precipitating antibody directed against native arginase, circulated at the same level as in virgin animals. The attachment of PEG to arginase altered its kinetic properties.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 454671     DOI: 10.1016/0005-2795(79)90111-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.

Authors:  Everett Stone; Lynne Chantranupong; Candice Gonzalez; Jamye O'Neal; Mridula Rani; Carla VanDenBerg; George Georgiou
Journal:  J Control Release       Date:  2011-10-06       Impact factor: 9.776

2.  Emerging synthetic approaches for protein-polymer conjugations.

Authors:  Rebecca M Broyer; Gregory N Grover; Heather D Maynard
Journal:  Chem Commun (Camb)       Date:  2011-01-12       Impact factor: 6.222

3.  Evolution of drug delivery systems: From 1950 to 2020 and beyond.

Authors:  Haesun Park; Andrew Otte; Kinam Park
Journal:  J Control Release       Date:  2021-12-29       Impact factor: 11.467

Review 4.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

Review 5.  Polymer conjugates. Pharmacokinetic considerations for design and development.

Authors:  R Duncan; F Spreafico
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

Review 6.  Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery.

Authors:  Matthew Palombo; Manjeet Deshmukh; Daniel Myers; Jieming Gao; Zoltan Szekely; Patrick J Sinko
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013-10-23       Impact factor: 13.820

7.  Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC).

Authors:  Sam-Mui Tsui; Wai-Man Lam; Tin-Lun Lam; Hiu-Chi Chong; Pui-Kin So; Sui-Yi Kwok; Simon Arnold; Paul Ning-Man Cheng; Denys N Wheatley; Wai-Hung Lo; Yun-Chung Leung
Journal:  Cancer Cell Int       Date:  2009-04-17       Impact factor: 5.722

Review 8.  Site-Specific PEGylation of Therapeutic Proteins.

Authors:  Jonathan K Dozier; Mark D Distefano
Journal:  Int J Mol Sci       Date:  2015-10-28       Impact factor: 5.923

Review 9.  T cell epitope: friend or foe? Immunogenicity of biologics in context.

Authors:  Constanze A Weber; Preema J Mehta; Matt Ardito; Lenny Moise; Bill Martin; Anne S De Groot
Journal:  Adv Drug Deliv Rev       Date:  2009-07-18       Impact factor: 15.470

10.  Human Recombinant Arginase I [HuArgI (Co)-PEG5000]-Induced Arginine Depletion Inhibits Colorectal Cancer Cell Migration and Invasion.

Authors:  Houssam Al-Koussa; Maria Al-Haddad; Ralph Abi-Habib; Mirvat El-Sibai
Journal:  Int J Mol Sci       Date:  2019-11-29       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.